44 results about "Mouse Mammary Gland" patented technology

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol / L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol / L. The application is helpful for the development of novel antitumor drugs.

The invention relates to a use of an miR-100 inhibitor in cancer metastasis reduction, and concretely relates to a use of a reagent for determining the miR-100 expression level in the preparation of breast cancer diagnosis reagents, and a use of the miR-100 inhibitor, and a use of the miR-100 inhibitor or an miR-100 antagonist in the preparation of medicines for treating breast cancer. Up-regulation of miR-100 in in-vivo tumor related macrophages and in-vitro induced M2 type macrophages is induced by tumor micro-environment. In in-vivo test, the microRNA antagonist knocks down the expression of the miR-100 in mouse mammary gland tumor tissues, and a case that in-situ tumor growth has no statistic difference, the quantity of lung metastasis tubercles is obviously down-regulated and the mammary gland tumor metastasis is inhibited in an experiment group of the miR-100 down-regulation in the tumor related macrophages is found.

The invention relates to the technical field of antineoplastic drugs, and in particular discloses application of combination of a TLR7 agonist and a tyrosine kinase inhibitor in preparing the antineoplastic drugs. The TLR7 agonist has a structure as shown in formula (I); and the tyrosine kinase inhibitor, which is lapatinib, has a structure as shown in formula (II). According to embodiments, experimental results show that the TLR7 agonist, in combination with the lapatinib, shows a significant synergistic treatment effect on treating a model of mice mammary cancer.

The invention discloses a transgenic cell with in-vivo tracking and oncotherapy functions and a preparation method thereof. The transgenic cell is a mesenchymal stem cell from a human umbilical cord, is capable of performing oncotherapy, has a molecular imaging function, and is capable of monitoring the body distribution and survival condition in real time in a living body state after being subjected to intratumor injection. Particularly, a renilla luciferase-red fluorescence protein-suicide gene thymidine kinase fusion gene is transfected in the mesenchymal stem cell from the human umbilical cord, and a fluorescein signal is collected by means of a living body imaging system to monitor targeted therapy of a Nude mouse breast cancer model; a mouse injected with the mesenchymal stem cell transfected with the fusion gene is administrated with a substrate ganciclovir of thymidine kinase, and the death of tumor cells around the mesenchymal stem cell is induced through the bystander effect.

The invention discloses a composition with a Staphylococcus aureus resisting effect. The composition consists of general flavone of sophora flavescens and general flavone of liquorice. The general flavone parts of sophora flavescens and liquorice are prepared through extraction, extraction, enrichment and the like, and are compounded. The results of in-vitro research shows that the composition directly inhibits the growth of gram-positive bacteria such as Staphylococcus aureus and can reduce the formation of biofilms and the content of staphyloxanthin; the results of in-vivo studies prove thatthe composition can obviously reduce mammary gland alveolar hyperplasia and alveolar inflammatory cell infiltration of mice caused by Staphylococcus aureus infections, and significantly reduce the bacterium carrying amount of mouse mammary gland tissues of each model group and the content of IL-1 beta, IL-2 and TNF-alpha inflammatory factors in the mammary gland tissues. According to the invention, the comprehensive utilization of medicinal materials including sophora flavescens and liquorice and the quality and efficiency improvement of the industry can be realized; the waste is turned intothe wealth; and the composition has good economic effects and social benefits, and accords with the sustainable development strategy in China.

The invention relates to application of miR-124 in mammary cancer bone metastasis diseases. The application comprises application of miR-124 in preparing tools for prognosing mammary cancer bone metastasis risk and diagnosing whether mammary cancer metastasis occurs, and application of miR-124 in preparing drugs for preventing and / or treating mammary cancer bone metastasis. In the invention, the expression of the miR-124 in mammary cancer cells with different bone metastasis capabilities and mouse mammary cancer bone metastasis tissues is detected to determine the relationship between the miR-124 and mammary cancer bone metastasis preliminarily; the expression of the miR-124 in tumor cells is exogenously enhanced or inhibited, and the actions of the miR-124 on osteoblasts and osteoclasts are observed, thereby further determining that the miR-124 can inhibit the mammary cancer bone metastasis by regulating the interactions between the mammary cancer cells and the bone microenvironment. The invention verifies the actions of the miR-124 in mammary cancer bone metastasis, and provides a new target for treating mammary cancer bone metastasis.

The invention belongs to the fields of animal cell genetic engineering and gene genetic modification, and particularly relates to a construction method and application of an HER2 gene humanized mousetumor cell model. The method uses a CRISPR technology to knock out a mouse HER2 gene, and uses slow viral infection to insert a humanized HER2 gene into mouse breast cancer cell 4T1. The HER2 humanized mouse breast cancer humanized tumor model constructed by the method can be used not only for evaluation of antibody tumor drug efficacy, but also has important guiding significance for a clinical effect of drug development; and at the same time, the model is also an ideal model for safety evaluation of anti-human HER2 antibody drugs, pre-clinical in-vivo evaluation is performed on toxicology ofHER2 antibody drugs and HER 2-CAR T, HER 2-CAR NK immune cell therapy, and the market gap is filled.

The invention discloses a mouse mammary gland syringe needle and application thereof. The mammary gland syringe needle is prepared by performing hot stretch deformation on a head portion of a pipettor tip and truncating a fine tubular structure formed by the stretching portion. Materials of the prepared mammary gland syringe needle are easily available, the injection effect is ideal, research materials can be provided for mammary gland pathology research. Compared with a traditional injection method that easily causes mammary gland mechanical damage or needs an expensive micro-syringe, the mouse mammary gland syringe needle has wider application value.

The invention discloses a construction method and application of a mycoplasma bovis mouse mastitis model. The construction method of the mouse mastitis model comprises the following step of inoculating an infection solution to mammary glands of a mouse in a lactation period, wherein the infection solution is obtained by suspending mycoplasma bovis NMH7 strains by using a sterile buffer solution, specifically, the inoculation manner can be inoculation through mouse milk ducts, and specifically, the mammary glands of the mouse are the fourth pair of mammary glands of the mouse. The invention also relates to the application of N-acetyl-L-cysteine in preparation of medicines for treating mycoplasma bovis cow mastitis. The model constructed by the method can simulate pathological changes of cow mammary glands when the mycoplasma bovis cow mastitis occurs clinically, good repeatability and convenience are achieved, and good practical application value is achieved.

The invention discloses an experimental method for promoting animal mammary gland development by using vitamin B3. The method includes the following steps: S1, selecting 20 pregnant female mice, performing single culture, performing 12h:12h day and night discontinuous lighting, and performing free feeding and drinking; S2, taking care born mice by mother mice for four weeks after pregnant mice delivery, performing artificial weaning on the mice, and dividing the mice into two groups including a NT group (10) and a vitamin B3 group (10), wherein the feeding conditions of the NT group remain unchanged, and 0.5% of the vitamin B3 is added into daily feed of the vitamin B3 group; and S3, after the mice are fed for three weeks, killing the mice by cervical dislocation, and taking fourth pairs of mammary glands of the mice for Whole mount staining. According to the method for promoting the adolescent mammary gland development by using the vitamin B3, through in-vivo and in-vitro experiments,the proliferation and cyclin expression of EPH4EV cells and mouse mammary glands are detected, the molecular biology is used to comprehensively evaluate the effects of the vitamin B3 on the EPH4EV proliferation and mouse mammary gland development, and results show that the vitamin B3 can significantly promote the expression of cell proliferation markers in the cells and mouse mammary glands, thereby promoting the cell proliferation and mammary gland development.

The invention discloses a traditional Chinese medicine ointment for treating mastitis. The traditional Chinese medicine ointment comprises the following raw materials in parts by weight: 4g of menthol, 50g of herba violae, 50g of herba taraxaci and 2g of borneol. According to the application and the method of the traditional Chinese medicine ointment for treating the mastitis, a damage condition of mammary tissue is evaluated by mammary tissue paraffin sectioning and H-E staining methods, and the activity of MPO (myeloperoxidase) of mammary tissue and the expression level of inflammatory factors in the mammary tissue are detected, which proves that the traditional Chinese medicine ointment can relieve damage to the mammary tissue of a mouse; inhibits mammary gland tissue inflammatory cell infiltration and inflammatory factor expression and relieves the atrophy of mammary gland acinus, thereby effectively showing that the traditional Chinese medicine ointment can relieve the inflammatory reaction of mammary gland and has a good treatment effect on LPS-induced mouse mastitis.

The invention relates to an extraction method for dalbergia sissoo. The dalbergia is leguminosae dalbergia genus plant Dalbergia sissoo Roxb. Extracts contain an alcohol extract, an ethyl ether extract, and a petroleum ether extract. A monomer separated in the extracts is 4-methoxydalbergione. The method specifically includes the following steps: taking dalbergia sissoo heartwood, performing planing to form thin sheets, performing crushing, performing sieving by using a No.2 sieve, and performing reflux extraction under heating for 2-5 times, wherein the extraction solvent is an ethanol or methanol solution, the material-liquid ratio is 1:2 to 1:8, and each time is maintained for 1-3 h; and performing filtration when the solution is hot, combining the filtrates, and performing reduced-pressure concentration to form a thin extract shape. Cell experiments confirm that the dalbergia sissoo has important medicinal value, and the monomer can significantly inhibit the proliferation of humanliver cancer cells HepG2, human breast cancer cells MCF-7, mouse breast cancer cells 4T1 and human glioma cells U87, and affect the morphological functions; and the method provides the basis for the development and utilization of the dalbergia sissoo and provide a novel option for the development of anti-tumor drugs.

The invention relates to DNA based on FAPalpha and survivin and application of the DNA based on the FAPalpha and the survivin in production of a tumor vaccine, in particular to a fused sequence, whichcan be secreted and expressed, shown in SEQ ID NO: 1 as shown in the description of an FAPalpha segment and a survivin segment and application of a DNA vaccine constructed on the basis of the sequence shown in SEQ ID NO: 1 as shown in the description in production of a therapeutic tumor vaccine, and belongs to the field of tumor DNA vaccines. According to the fused sequence, which can be secretedand expressed, shown in SEQ ID NO: 1 as shown in the description of the FAPalpha segment and the survivin segment and application of the DNA vaccine constructed on the basis of the sequence shown inSEQ ID NO: 1 as shown in the description in production of the therapeutic tumor vaccine, through an anti-tumor experiment, it is determined that compared with an individual FAPalpha vaccine and an individual survivin vaccine, the DNA vaccine has higher anti-tumor activity, and shows excellent anti-tumor effects on a mice breast cancer model and a mice pancreatic cancer model, so that the sequenceshown in SEQ ID NO: 1 as shown in the description has better application prospects in production of various tumor vaccines.

The invention relates to a mouse DCF1 specific polyclonal antibody and a preparation method of the of mouse DCF1 specific polyclonal antibody. The specific polyclonal antibody is obtained by binding a polypeptide specificities of 44th-76th amino acid residues in SEQ I DNO: 2. The antibody can detect the expression difference of the murine breast carcinoma cell 4T1 and DCF1 in the normal murine mammary tissue; the prepared polyclonal antibody can detect protein expression reduction of DCF1 after inhibiting cancer cell of 4T1 by JNKinhibitor II, therefore, which shows that the polyclonal antibody can be used for detecting the expression level of the DCF1 of the murine breast cancer at different states.

The invention discloses a macrophage-based living cell drug-carrying system, a preparation method and application thereof. The macrophage-based live cell drug delivery system comprises macrophages, anchored chemotherapeutic drugs and anchored cytolytic groups. The preparation method includes the following steps: taking mouse bone marrow cells, culturing them in vitro, adding recombinant mouse macrophage colony stimulating factor and mouse breast cancer 4T1 cell culture supernatant or lipopolysaccharide LPS into the culture medium, and continuing to culture, Induce macrophage polarization to obtain regulatory M1 or M2 macrophages; co-incubate anchored chemotherapeutic drugs and anchored cytolytic groups in macrophage culture medium to prepare macrophage-based Live cell drug delivery system. The macrophage-based living cell drug-loading system prepared above can actively target the lung metastasis site of breast cancer, and effectively inhibit the lung metastasis of breast cancer.

The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers.

The invention relates to a mouse DCF1 specific polyclonal antibody and a preparation method of the of mouse DCF1 specific polyclonal antibody. The specific polyclonal antibody is obtained by binding a polypeptide specificities of 44th-76th amino acid residues in SEQ I DNO: 2. The antibody can detect the expression difference of the murine breast carcinoma cell 4T1 and DCF1 in the normal murine mammary tissue; the prepared polyclonal antibody can detect protein expression reduction of DCF1 after inhibiting cancer cell of 4T1 by JNKinhibitor II, therefore, which shows that the polyclonal antibody can be used for detecting the expression level of the DCF1 of the murine breast cancer at different states.

The invention provides a method for overexpression of cholate activation lipase in mammary gland of a mammal. The method comprises the following steps of transferring the gene coding human cholate activation lipase into the mammal so as to realize overexpression of human cholate activation lipase in the mammary gland of the mammal. According to the method, a transgenic mouse is prepared by utilizing construction of a BSSL (bile salt stimulation lipase) mammary gland specific expression vector; and human cholate activation lipase is overexpressed in the mammary gland of the mouse, the expression quantity of the human cholate activation lipase in milk of the transgenic mouse can achieve 0.38mg / ml, and the activity is 91473.94mU / ml. A premature young mouse is fed with transgenic milk of high expression cholate activation lipase, and the result shows that the survival rate of the premature young mouse is improved by 10% compared with that of the premature young mouse fed with milk of wild mouse. The method lays a foundation for producing human cholate activation lipase by utilizing a large livestock mammary gland bioreactor.

The invention belongs to the field of pharmaceutical preparations, in particular to a nano-immune preparation based on porous calcium carbonate, which uses porous CaCO 3 The nanoparticle is the carrier, and the inside of the hole is loaded with the immune blocking inhibitor IDOi, covered by the liposome layer, and the surface of the liposome layer carries the immune regulation nucleic acid CpG ODNs. The nano-immune preparation synthesized by the invention has good biocompatibility and high safety, has a good effect on treating breast cancer in mice and preventing cancer recurrence, the preparation process is simple and easy to realize, and has good application in the field of anti-tumor drug preparation. prospect.

The invention relates to a plant lignan or enterolactone and PD-1 / PD-L1 inhibitor combined pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. In order to solve the problem that malignant tumor patients are insensitive to immunotherapy, the invention provides a plant lignan or enterolactone and PD-1 / PD-L1 inhibitor combined pharmaceutical composition which comprises an effective dose of a plant lignan preparation or an enterolactone preparation and an effective dose of a PD-1 / PD-L1 inhibitor. The combined pharmaceutical composition disclosed by the invention can increase the proportion of immune cells with an anti-cancer function and inhibit immune escape of cancer cells. The proportion of CD4 and CD8 positive cells can be up-regulated through combined medication, and the effect of inhibiting growth of mouse breast cancer is superior to that of independent medication of plant lignans, enterolactone or PD-L1 / PD-1 inhibitors. The invention provides an unprecedented effective auxiliary or synergistic treatment strategy for immunotherapy of malignant tumors.

The invention discloses an isolated culture and subculture method of mouse breast cancer cells and belongs to the technical field of isolated culture methods of animal cells. The method comprises the following steps: cleaning in-vitro fresh mouse breast cancer tissue fragments subjected to pretreatment, and putting the cleaned in-vitro fresh mouse breast cancer tissue fragments into a collagenase I solution for digestive treatment; after the digestive treatment, adding culture, carrying out centrifuging, and reserving a precipitate; transferring the obtained precipitate into a culture bottle, carrying out culturing in an incubator, and beginning to change the liquid for the first time after carrying out culturing for 48 hours; after the culture is finished, removing non-adherent cells to obtain target cells; and replacing the culture medium, then, culturing the target cells, and after the target cells form a cell colony, obtaining subculturable mouse breast cancer cells. Under the condition of ensuring the purity of isolated culture of the primary cells, an isolated culture of the primary cells is shortened and simplified. According to the method, a frequent liquid change mode at an early stage of primary isolated culture in the prior art is adjusted to be complete liquid change for the first time in 48 hours, so that the liquid change frequency is greatly lowered.

The invention belongs to the technical field of molecular biology, and relates to a construction method and application of a mouse mammary tissue miRNA overexpression model. A miRNA exogenous reagent-bta-16b-agomiR is injected through mammary tissue by adopting a microsyringe, a mouse is killed 48 hours after injection, RNA is extracted from the mammary tissue by using chloroform, reverse transcription is performed to obtain cDNA, and the overexpression effect of the bta-16b-agomiR and the mRNA expression levels of PGLYRP1 and PTX3 are detected by using fluorescent quantitative PCR; and the mammary tissue is subjected to HE staining and PGLYRP1 and PTX3 immunohistochemical tests. The method disclosed by the invention can be widely applied to overexpression of miRNA in the mouse mammary tissue and related research of the miRNA in living tissue, and a model basis is provided for tests of pathology mechanisms, immune mechanisms and the like of mastitis related diseases.

The invention provides a construction method and application of a breast cancer cell strain orthotopic transplantation model, and relates to the technical field of biology. According to the construction method of the breast cancer cell strain orthotopic transplantation model, firstly, a syringe is used for inserting a needle from a single-side nipple of a fifth pair of nipples of a mouse, then a breast cancer cell solution is injected into the fourth pair of nipples on the same side to the root of a rear leg of the mouse after the needle is inserted into the skin, and the breast cancer cell strain orthotopic transplantation model is constructed. According to the invention, a special subcutaneous inoculation mode is designed according to the structural characteristics of a mouse mammary tissue anatomical map, so that the non-invasive subcutaneous injection type in-situ inoculation can be realized, the accurate in-situ tumor formation can be ensured, and the success rate of the in-situ model is improved. The construction method disclosed by the invention is simple to operate, the limitation of a common inoculation mode in the current market is solved, and greater possibility is provided for large-scale and repeatable construction of the breast cancer mouse model.

The invention discloses a codon optimized beta-galactosidase gene and an application thereof and belongs to the technical field of biochemistry and molecular biology. The nucleotide sequence of beta-galactosidase is shown as a sequence table SEQ ID NO.1. According to the preference of relevant high-expression protein codons in cow milk, codons of the bacterium-derived beta-galactosidase gene are optimized. The optimized OLacZ gene is verified in mouse mammary epithelial cells, and it is proved that the expression quantity of the gene is remarkably increased by about 3.7 times compared with that of a wild LacZ gene. The codon optimized OLacZ gene can be better effectively expressed in mammary tissue of a mother mouse in a lactation period. Beta-galactosidase serves as a reporter gene and is efficiently expressed in cow mammary tissue, and the effective tool gene is provided for further developing a mammary gland bioreactor.